Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

计划入组 290 人 · 首次发布于 2025 年 9 月 24 日

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

计划入组 120 人 · 首次发布于 2024 年 1 月 17 日

Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

计划入组 35 人 · 首次发布于 2026 年 7 月 8 日

HER2+ Breast Cancer(Diakonos)

CLX-001

oncology program (HER2+ breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

FDA Accepts Datopotamab Deruxtecan BLA for HR-Positive, HER2-Negative Metastatic Breast Cancer

Landmark Breast Cancer Trials Reshape Treatment Paradigms for HR-positive, HER2-negative Disease

Roche's Giredestrant Falls Short in Phase 2 Breast Cancer Trial, Raising Questions About Oral SERD Class